Results 81 to 90 of about 234,967 (265)
Shared differential metabolites identified across the three sample groups. (A) Venn diagram of differential metabolites between the two comparison groups; Based on the detected levels of these overlapping differential metabolites, (B) d‐Arabitol, (C) Triclosan, (D) Iloprost, (E) Tetracosanoic acid, and (F) Omeprazole sulfone. Box plots were constructed
Mengtao Qian +4 more
wiley +1 more source
Lipid Abnormalities Associated With Stroke
Association of dyslipidemia with stroke is conflicting though recent studies point to their positive role. Sixty consecutive patients with stroke were analyzed for fasting lipid profile values.
Thacker Anup K +3 more
doaj
Abstract Background Arterial stiffness is a crucial factor in determining an increase in systolic blood pressure and pulse pressure and can also predict the development of cardiovascular disease (CVD). The purpose of this study was to examine the relationship between arterial stiffness and future CVD.
Susan Darroudi +10 more
wiley +1 more source
Aim. To study the features of lipid metabolism disorders in patients with acute coronary syndrome (ACS), depending on glomerular filtration rate (GFR) and smoking factor. Materials and methods. The study included 142 ACS patients (mean age – 59.66 ± 0.
O. V. Yadzhyn, T. M. Solomenchuk
doaj +1 more source
Abstract Background There are limited data on the efficacy of smartphone‐based personal health records (PHRs) in patients with cardiovascular disease. This study aimed to examine the processes, outcomes and challenges associated with the implementation of integrated PHRs in patients with heart failure (HF) or coronary artery disease (CAD). Methods This
Kotaro Nochioka +16 more
wiley +1 more source
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia +2 more
wiley +1 more source
Background/Objectives: Non-high-density lipoprotein (non-HDL) cholesterol provides a practical alternative for assessing dyslipidemia, with the advantage of not requiring fasting.
Hyo-Kyoung Nam +3 more
doaj +1 more source
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller +8 more
wiley +1 more source
Endothelial Function in Dyslipidemia: Roles of LDL-Cholesterol, HDL-Cholesterol and Triglycerides. [PDF]
Higashi Y.
europepmc +1 more source
Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen +7 more
wiley +1 more source

